Orthoson develops a micro-invasive bio-structural gel designed to treat lower back pain and degenerative disc disease by restoring the mechanical and biological function of intervertebral discs. The injectable treatment targets patients suffering from disc degeneration, aiming to provide immediate pain relief and restore a healthy disc environment.
Subscribe to see Orthoson’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Orthoson is a medical devices company. It has raised at least $35.4M across the 3 funding rounds on record. Its most recent funding round, Series A, raised $11M in May 2022. Xcout tracks 10 named people at Orthoson, including Rich Simmonds (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
4 more named people on record for Orthoson, with roles, board committees and tenure — see the full roster →
At least $35.4M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $11M | 1 named | |
| Series A | $12.2M | 2 named | |
| Series B | $12.2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 2 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of Orthoson's closest competitors — see the full list of competitors and alternatives →
Nanochon, Inc. is a privately held biotechnology company developing advanced implant technologies for joint repair and regeneration. The company is headquartered in Washington, D.C.
Purgo Scientific is a medical device company that develops localized, sustained drug delivery devices designed to treat orthopedic biofilm infections and fracture-related infections. Their lead preclinical product, the Purgo Pouch, is a combination product intended to sustain local antibiotic therapy, kill biofilms, and expedite wound healing.
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
ORTHOREBIRTH Co., Ltd. is a Japanese medical and research corporation headquartered in Yokohama, Kanagawa-ken, Japan. The company applies advanced microfiber technology to develop innovative regenerative medical products, including cotton-shaped bone regeneration materials and artificial bone fillers like ReBOSSIS-MT.
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell therapy, advanced drug delivery systems, and surgical interventions. This Tokyo-based firm was established in 2004.
Colorado Therapeutics LLC is a medical device company that develops proprietary cross-linked tissue products and biologic implants for soft tissue repair. The company serves the medical and healthcare sector by providing advanced technological solutions for surgical applications.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Orthoson? Suggest a correction · Work at Orthoson? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.